Immunoglobulin G1

Athens Research

Immunoglobulin G1

9

ELISA, In Vitro Diagnostic, Glycoproteomics, Biotherapeutics, Inflammation, Infection, Flow Cytometry, Autoimmune Disease, Cancer

Research Use Only

≥95% by SDS-PAGE

IgG1, constituting 65% of serum IgG, is the predominant subclass critical for adaptive immunity, characterized by a flexible hinge region enabling broad antigen recognition and potent effector functions. Its Fc domain binds FcgammaRI/III receptors and C1q, driving antibody-dependent cellular cytotoxicity (ADCC), phagocytosis, and complement activation. In multiple myeloma, monoclonal IgG1 overproduction disrupts normal immunoglobulin synthesis, often manifesting as renal impairment or hyperviscosity syndrome. Serum IgG1 quantification aids in monitoring disease progression and treatment efficacy, with elevated ratios of IgG1/IgG (more then65%) signaling clonal plasma cell expansion. Autoimmune pathologies like systemic lupus erythematosus (SLE) and Sjögren’s syndrome exhibit IgG1-predominant autoantibodies targeting nuclear antigens, exacerbating tissue inflammation via FcgammaR-mediated leukocyte activation. Conversely, IgG1 deficiencies (less then4.9 g/L) predispose to recurrent bacterial infections due to impaired opsonization of protein antigens like tetanus toxoid. Therapeutically, myeloma-derived IgG1 serves as a standardized reagent in immunoassays and structural studies, leveraging its intact glycosylation patterns. Dysregulated IgG1 also underpins type II hypersensitivity reactions, with FcgammaRIII cross-linking on mast cells/basophils driving anaphylactic pathways. By balancing immune activation and homeostasis, IgG1 remains pivotal in both pathogenic mechanisms and biotherapeutic innovation.

more then 1 year

Source human myeloma plasma non-reactive for HBsAG, anti-HCV, anti-HBc, and negative for anti-HIV 1 & 2 by FDA approved tests.

≤ -80° C

41116100